SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome

COVID-19: a modern trigger for Guillain-Barre syndrome, myasthenia gravis, and small fiber neuropathy

“…The most important message is that the benefits of vaccine administration continue to outweigh risks in terms of overall mortality and GBS incidence ( Abolmaali et al, 2022 ). Recent meta-analysis including 48 publications including 2,110,441,600 participants revealed COVID vaccine related GBS at a rate of 3.09 per 1 million people within 6 weeks of vaccination, higher to that of the influenza vaccine ( Finsterer et al, 2022 ).…”

Neuro-COVID is a serious complication of SARS-CoV-2 infections and can determine the long-term outcome of COVID-19

“…Missing is a discussion about the prevalence of neuro-COVID since introduction of the various anti-SARS-CoV-2 vaccinations. There are indications that, at least for SARS-CoV-2-related Guillain-Barre syndrome, its prevalence has declined since introduction of world-wide vaccination campaigns (3).…”

Musculoskeletal complications of COVID-19 can contribute to its morbidity and mortality

“…Another musculoskeletal complication of SARS-CoV-2 infections or vaccination that was not discussed in the review article is Guillain-Barre syndrome (GBS). 4 Although neuropathies have been mentioned generally, GBS deserves special attention as it can be complicated by respiratory muscles involvement and may require mechanical ventilation. In addition, involvement of the respiratory muscle in GBS can easily be confused with SARS-CoV-2 pneumonia as both conditions can coexist in the same patient.…”